Targeting MYC through WDR5

Lance R Thomas; Clare M Adams; Stephen W Fesik; Christine M Eischen; William P Tansey

doi:10.1080/23723556.2019.1709388

Targeting MYC through WDR5

Mol Cell Oncol. 2020 Jan 10;7(2):1709388. doi: 10.1080/23723556.2019.1709388. eCollection 2020.

Authors

Lance R Thomas¹, Clare M Adams², Stephen W Fesik³, Christine M Eischen², William P Tansey^{1

3}

Affiliations

¹ Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN, USA.
² Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
³ Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, USA.

Abstract

The oncoprotein transcription factor MYC is overexpressed in most cancers and is responsible for hundreds of thousands of cancer deaths worldwide every year. MYC is also a highly validated - but currently undruggable - anti-cancer target. We recently showed that breaking the interaction of MYC with its chromatin co-factor WD repeat-containing protein 5 (WDR5) promotes tumor regression in mouse xenografts, laying the foundation for a new strategy to inhibit MYC in the clinic.

Keywords: Cancer; Cancer therapy; MYC; WDR5.

Abstract

Grants and funding